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Grainyhead-like 2 inhibits the coactivator
p300, suppressing tubulogenesis and the
epithelial–mesenchymal transition
Phillip M. Pifera, Joshua C. Farrisa, Alyssa L. Thomasa, Peter Stoilovb, James Denvirc,
David M. Smithb, and Steven M. Frischa,b,*
a

Mary Babb Randolph Cancer Center and bDepartment of Biochemistry, West Virginia University, Morgantown,
WV 26506; cDepartment of Biochemistry and Microbiology, Marshall University, Huntington, WV 25755

ABSTRACT Developmental morphogenesis and tumor progression require a transient or
stable breakdown of epithelial junctional complexes to permit programmed migration, invasion, and anoikis resistance, characteristics endowed by the epithelial–mesenchymal transition (EMT). The epithelial master-regulatory transcription factor Grainyhead-like 2 (GRHL2)
suppresses and reverses EMT, causing a mesenchymal–epithelial transition to the default
epithelial phenotype. Here we investigated the role of GRHL2 in tubulogenesis of Madin–
Darby canine kidney cells, a process requiring transient, partial EMT. GRHL2 was required for
cystogenesis, but it suppressed tubulogenesis in response to hepatocyte growth factor. Surprisingly, GRHL2 suppressed this process by inhibiting the histone acetyltransferase coactivator p300, preventing the induction of matrix metalloproteases and other p300-dependent
genes required for tubulogenesis. A 13–amino acid region of GRHL2 was necessary for inhibition of p300, suppression of tubulogenesis, and interference with EMT. The results demonstrate that p300 is required for partial or complete EMT occurring in tubulogenesis or tumor
progression and that GRHL2 suppresses EMT in both contexts through inhibition of p300.
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INTRODUCTION
The protein p300 is a coactivator of transcription that interacts with
at least 400 DNA factors to activate transcription from thousands of
enhancers/promoters, mostly contingent upon its intrinsic histone
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miMCD, mouse inner medullary collecting duct; MMP, matrix metalloprotease;
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acetyltransferase (HAT) activity. In this context, it is viewed as an
“integrator” factor that serves as a nexus among multiple signaling
pathways and programs of gene expression (Kamei et al., 1996; Vo
and Goodman, 2001; Bedford et al., 2010; Yao et al., 2013). Accordingly, p300/CREB-binding protein (CBP)–null mice die at embryonic
days 9.5–11.5 with massive deficits of mesenchymal cells and erythroid cells, as well as with defects in neurulation and heart development (Oike et al., 1999; Yao et al., 2013). p300 is essential for the
differentiation of muscle, erythroid lineages, osteoblast, oligodendrocytes, and stem cells (Puri et al., 1997; Oike et al., 1999; Blobel,
2000; Polesskaya et al., 2001; Narayanan et al., 2004; Teo and Kahn,
2010; Zhang et al., 2016). A recent study showed that p300 is a
marker for superenhancers, positioning it to control cell state transitions (Witte et al., 2015).
Grainyhead-like 2 (GRHL2) is one of the three genes comprising
a family of mammalian transcription factors related to Drosophila
Grainyhead, the first zygotically encoded transcription factor expressed during the maternal-to-zygotic transition (Harrison et al.,
2010). GRHL2 is important for epithelial barrier assembly in, for example, the morphogenesis of kidney collecting ducts, placenta, lung
alveoli, and the mammary gland ductal system (through OVOL2, a
GRHL2 target gene) (Gao et al., 2013; Watanabe et al., 2014;
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Aue et al., 2015; Walentin et al., 2015). Grainyhead-like factors are
also critical for diverse developmental events that involve the formation of epithelial barriers, including epidermal assembly, neural crest
formation, and, in the adult, wound healing (Wilanowski et al., 2002;
Gustavsson et al., 2008; Wang and Samakovlis, 2012; Mlacki et al.,
2015). GRHL2 activates the expression of multiple genes encoding
epithelial cell adhesion molecules (e.g., E-cadherin, desmosomal
proteins, tight junction proteins) and, due to its widespread expression, may be generally important for enforcing an epithelial phenotype (Wilanowski et al., 2002; Ting et al., 2003, 2005; Auden et al.,
2006; Rifat et al., 2010; Werth et al., 2010; Boglev et al., 2011; Cieply
et al., 2012; Senga et al., 2012; Tanimizu and Mitaka, 2013; Aue
et al., 2015). Correspondingly, GRHL2 expression plays an important
role in suppressing the oncogenic EMT, thereby functioning as a tumor suppressor that enhances anoikis sensitivity (Cieply et al., 2012,
2013; Mlacki et al., 2015); in fact, the gene most tightly correlated
with E-cadherin expression is GRHL2 (Kohn et al., 2014).
The opposing roles of GRHL2 in establishing the epithelial state
versus p300 in differentiation—including EMT—motivated us to investigate a potential role for GRHL2 in inhibiting p300 function. Kidney tubulogenesis is contingent upon temporal and spatial regulation of epithelial cells, in which GRHL2, which is expressed in the
ureteric buds of the developing kidney, plays a critical organizing
role (Schmidt-Ott et al., 2005; Aue et al., 2015; Walentin et al.,
2015). Madin–Darby canine kidney (MDCK) tubulogenesis in response to hepatocyte growth factor (HGF) models some aspects of
kidney collecting-duct tubulogenesis in vivo and requires a transient, partial EMT (Pollack et al., 1998, 2004; O’Brien et al., 2002;
Leroy and Mostov, 2007; Hellman et al., 2008; Jung et al., 2012;
Zhang et al., 2014). HGF causes MDCK cells to undergo cell scattering in two-dimensional culture and induces tubulogenesis of MDCK
cysts that form in a three-dimensional collagen gel (Wang et al.,
1990; Pollack et al., 2004). Induction of MMP1 and MMP13 by HGF
through AP1/p300 complexes is required for tubulogenesis in the
MDCK model (Benbow and Brinckerhoff, 1997; Clark et al., 2008;
Hellman et al., 2008; Chacon-Heszele et al., 2014). Targeted knockout studies indicate a role for HGF/Met in kidney development, and,
relatedly, HGF/Met signaling is a potent stimulator of Wnt signaling,
a crucial signaling pathway in this process, validating the in vivo
relevance of this approach (Monga et al., 2002; Bridgewater et al.,
2008; Ishibe et al., 2009).
Here we report that GRHL2 promoted cystogenesis but suppressed tubulogenesis. GRHL2 protein interacted functionally with
p300, inhibiting its HAT activity and transcriptional activation of target genes, including matrix metalloproteases. A small (13 amino
acids [aa]) sequence of GRHL2 was important for inhibition of p300,
suppression of tubulogenesis, and reversal of EMT. These results
mechanistically position GRHL2, an enforcer of the epithelial default
phenotype, as an antagonist of p300, a coactivator of differentiation-specific genes, with important ramifications for developmental
and tumor biology.

RESULTS
GRHL2 suppresses cell scattering and tubulogenesis
In light of the epithelial programming role of GRHL2, we tested
the effect of HGF on GRHL2 levels in MDCK cells. We found that
HGF down-regulated the expression of endogenous GRHL2 protein
levels at early time points (Figure 1A). When constitutively expressed
in MDCK cells, GRHL2 significantly inhibited HGF-induced cell scattering compared with vector control cells (Figure 1B). Conversely,
MDCK cells with GRHL2 short hairpin RNA (shRNA) knockdown
demonstrated enhanced HGF-induced cell scattering; retention of
2480 | P. M. Pifer et al.

E-cadherin expression showed that EMT did not occur in response
to the knockdown of GRHL2 alone (Figure 1C and Supplemental
Figure S1 Video). GRHL2 had only modest effects on the phosphorylation status of two established HGF/Met signaling mediators, Erk
and Akt (Supplemental Figure S2).
We then examined the effects of GRHL2 on HGF-induced tubulogenesis in the three-dimensional collagen model. GRHL2 expression caused the formation of larger cysts than in vector control cells,
consistent with previous reports on hepatic bile duct cells (Figure 1D;
Tanimizu and Mitaka, 2013). GRHL2 significantly suppressed tubulogenesis/branching morphogenesis after HGF treatment (Figure 1D);
a similar effect of murine Grhl2 was observed in mouse inner medullary collecting-duct cell line (Supplemental Figure S3A), indicating
the important role of GRHL2 down-regulation in tubulogenesis. Conversely, the stable knockdown of GRHL2 prevented cystogenesis
(Supplemental Figure S3B), presumably by down-regulating epithelial adhesion molecules (Werth et al., 2010; Senga et al., 2012). Transient knockdown of GRHL2 after cyst formation using a doxycyclineinduced shRNA vector, however, clearly indicated that the loss of
GRHL2 promoted tubulogenesis (Supplemental Figure S4A). There
was no effect of the GRHL2 shRNA on cell proliferation (Supplemental Figure S4B). These results indicated that GRHL2 suppressed
HGF-activated cell scattering and tubulogenesis.

GRHL2 suppresses the expression of matrix
metalloproteases
To identify GRHL2 target genes responsible for the attenuation
of cellular responses to HGF/Met signaling, we used RNA-sequencing (RNA-Seq) to compare MDCK cells with constitutive
GRHL2 expression versus GRHL2 depletion with either no treatment or HGF induction (24 h). This experimental scheme allowed
for two distinct comparisons: genes regulated by HGF in the absence versus presence of GRHL2, and genes regulated by GRHL2
with versus without HGF induction. GRHL2 down-regulated
several known matrix metalloprotease (MMP) family members
(Table 1; confirmed by quantitative PCR [qPCR] in Figure 2A). In
light of the established importance of specific MMPs for tubulogenesis in the MDCK and mIMCD-3 cell culture models (Hotary
et al., 2000; Jorda et al., 2005; Hellman et al., 2008; ChaconHeszele et al., 2014), we verified their importance for branching
tubulogenesis in embryonic kidneys cultured ex vivo using the
generalized MMP inhibitor batimastat (Supplemental Figure S5).
The down-regulation of MMPs by GRHL2 contributed significantly to the tubulogenesis-suppressing effect of constitutive
GRHL2 expression, although additional contributions from EMT/
mesenchymal-epithelial transition (MET)–related GRHL2 genes
are likely.
To investigate the transcriptional mechanisms of MMP gene
regulation by GRHL2, we assayed MMP1 and MMP14 promoters
as luciferase reporter constructs by cotransfection in HT1080
fibrosarcoma cells, in which the endogenous MMPs are expressed constitutively (Tang and Hemler, 2004; Nonaka et al.,
2005). GRHL2 was found to suppress MMP1 and MMP14 promoters using adenovirus E1a protein, a known repressor of MMP
genes, as a positive control (Figure 2B). These results demonstrated that GRHL2 repressed MMP1 and MMP14 promoters;
however, examination of the promoter sequences used in our
reporter constructs did not indicate the presence of GRHL2
DNA–binding consensus sites (Wilanowski et al., 2002; Gao
et al., 2013; Aue et al., 2015; Walentin et al., 2015), suggesting
a subtler mechanism for repression not involving direct DNA
binding.
Molecular Biology of the Cell

FIGURE 1: GRHL2 suppresses HGF-induced cell scattering and tubulogenesis and is down-regulated by HGF. (A) HGF
induction down-regulates endogenous GRHL2 protein. Western blot and densitometric quantitation of HGF treatment
time course in MDCK cells. HGF induction down-regulates endogenous GRHL2 mRNA in MDCK cells; qPCR results
expressed as ratios compared with vector control. (B) Constitutive GRHL2 expression in MDCK cells suppresses
HGF-induced cell scattering; images represent representative morphologies of cells treated for 42 h. (C) GRHL2
knockdown in enhanced HGF-induced cell scattering (16 h), but MDCK shGRHL2 cells did not undergo an EMT
phenotypic change when EMT markers were examined via Western blotting. (D) Constitutive GRHL2 expression in
MDCK cells prevents tubulogenesis (blue, nuclei; green, actin). Scale bar, 20 μm. Quantification of percentage of cysts
that demonstrated tubulogenesis.

GRHL2 inhibits p300 function
The AP-1 transcription factor family is important in the regulation of
most MMP genes (Clark et al., 2008). GRHL2 significantly suppressed AP-1 activity on minimal reporter constructs in HT1080 and
293 cells (Figure 3A). GRHL2 did not appear to affect the expression
of FOS or JUN family members after HGF induction (Supplemental
Figure S6).
In light of the functional similarities between adenovirus E1a and
GRHL2 (see Discussion), we compared a published list of genes that
E1a down-regulated through p300 interaction (Ferrari et al., 2014)
against our list of GRHL2–down-regulated genes; the latter list was
derived from the RNA-Seq analysis that we performed on GRHL2expressing human mesenchymal subpopulation (MSP) cells (Farris
et al., 2016) and used because a comparison of canine versus human
gene lists proved uninformative for technical reasons. About 43.5%
of the genes that E1a repressed through p300 were also repressed
by GRHL2 (Figure 3B). Downstream Effector Analysis/Ingenuity
Pathway Analysis revealed that the expression of GRHL2 suppressed
the regulation of numerous p300-associated genes that were upregulated or down-regulated by HGF in the absence of GRHL2 expression (Figure 3C and Supplemental Figure S7). These results suggested that GRHL2 could potentially inhibit p300 function.
To investigate this, we assayed the effect of GRHL2 on the activity
of a GAL4-DNA binding domain–p300 fusion protein by transient
transfection using a GAL4-responsive luciferase promoter, an established method for testing p300 coactivator function without confounding effects from primary DNA-binding activator proteins
Volume 27 August 1, 2016

(Snowden et al., 2000). Adenovirus E1a protein repressed the AP-1
and GAL4/GAL4-p300 reporter activities, but a p300-nonbinding
mutant of E1a (Ferrari et al., 2014) failed to do so (Supplemental
Figure S8), validating the p300 dependence of transcription in these
assays. GRHL2 inhibited the coactivator function of p300 in this assay
(Figure 3D). As additional negative controls, GRHL2 did not affect
the ability of a p300-independent GAL4-activator fusion protein
(VP16-GAL4; Kutluay et al., 2009) to activate the same reporter; another transcription factor unrelated to GRHL2, c-Myc, failed to inhibit
GAL4-p300 function in this assay (Supplemental Figure S9). These
results indicated that GRHL2 was a potent suppressor of p300 function. The highly related GRHL1 and GRHL3 proteins had similar effects in the reporter assay (Supplemental Figure S10).

GRHL2 inhibits the histone acetyltransferase activity
of p300
The HAT domain of p300 acetylates numerous substrates, including lysines 18 and 27 in the N-terminal tail of histone 3
(H3; Ogryzko et al., 1996; Kasper et al., 2010; Jin et al., 2011). Using
recombinant proteins, we found that GRHL2 inhibited acetylation of
H3K27 by p300 in a dose-dependent way in vitro (Figure 4A). We
found similar results using the p300 HAT domain alone (aa 1283–
1673) rather than full-length p300 (Supplemental Figure S11). Recombinant GRHL1 and GRHL3 proteins also inhibited the HAT activity of p300 (Supplemental Figure S12).
To confirm these in vitro effects in cells, we analyzed histone
acetylation by chromatin immunoprecipitation (CHIP)–qPCR using
GRHL2 inhibits EMT through p300
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the human cell line HT1080 (because Encode reference data reporting histone acetylation are available for the human genome).
Consistent with the in vitro results, the acetylation of H3K27 was
inhibited in HT1080 cells expressing GRHL2 constitutively, specifically on promoters that GRHL2 repressed, including MMP1,
MMP14, MMP2, and ZEB1; acetylation of GRHL2-up-regulated
gene promoter–associated H3K27 was either not affected (CDH1,
ESRP1) or up-regulated (RAB25; Figure 4B). Unlike the effect of E1a
on p300, there was neither an effect of GRHL2 on global H3 acetylation nor global chromatin condensation, as assayed by Western
blotting (Figure 4B) or immunofluorescence localization of a LacImCherry-GRHL2 protein (Ferrari et al., 2014), respectively (Supplemental Figure S13).
GRHL2 interacted with p300 by the criteria of coimmunoprecipitation of transiently cotransfected genes or of endogenous proteins
(Figure 4C). The recombinant proteins interacted only weakly, however (Supplemental Figure S14), suggesting that the interaction is
transient or requires posttranslational modifications absent from our
recombinant proteins.

GRHL2 inhibits the C-terminal transactivation domain
of P300
Multiple domains of p300 can coactivate transcription independently. One of these is the C-terminal domain (aa 1665–2414),
which interacts with the p160 family of coactivators (Stiehl et al.,
2007). Previous reports suggested that the activity of the C-terminal
domain is stimulated by autoacetylation catalyzed by the p300 HAT
domain (Stiehl et al., 2007). In light of the HAT-inhibitory effect of
GRHL2 described above, we hypothesized that GRHL2 inhibited
the C-terminal domain through this mechanism. We confirmed that
transcriptional activation by the C-terminal domain, assayed as a
GAL4-C-term fusion protein, was stimulated by a cotransfected
p300 HAT domain and that the latter domain had no detectable
ability to activate transcription independently (Figure 5A). GRHL2
inhibited the enhanced transactivation by the p300 C-terminal domain in the presence of cotransfected p300 HAT (Figure 5B). Embedded within the C-terminal domain is a small subdomain called
Gene
regulated by
GRHL2

Fold change
(shGRHL2+HGF/
GRHL2+HGF)

Significance

MMP-1

31.7

Interstitial collagenase,
necessary for MDCK tubulogenesis, p300-dependent
expression

MMP-9

5.8

Gelatinase B, p300-dependent cancer invasiveness,
up-regulated in EMT

MMP-13

15.1

Collagenase 3, necessary
for MDCK tubulogenesis,
p300-dependent expression

MMP-14

5.82

Membrane-type MMP,
involved in EMT regulation
and invasiveness phenotype

MMP-19

3.5

Increases invasion in
multiple cancers

MMP-24

9.6

TABLE 1: HGF-induced MMP expression in the absence versus the
presence of GRHL2.
2482 | P. M. Pifer et al.

FIGURE 2: GRHL2 suppresses the induction of MMP genes and MMP
promoters by HGF. (A) GRHL2 suppresses the induction of MMP
genes (qPCR analysis; EN, endogenous GRHL2; CE, constitutively
expressed GRHL2; KD, GRHL2 shRNA knockdown). (B) GRHL2
suppresses the induction of MMP promoters by HGF. HT1080 cells
were cotransfected with either MMP1 or MMP14 promoter-luciferase
reporter constructs and GRHL2, E1A, or empty expression vectors.
Values represent relative luciferase activity normalized to TK-βgalactosidase control.

the IRF-3 binding domain (IBID; aa 2050–2096) that mediates the
interaction with the p160 coactivator family, including the family
member steroid receptor coactivator-1 (SRC-1; Sheppard et al.,
2001). Whereas neither the IBID domain of p300 nor SRC-1 alone
activated transcription efficiently, the combination of both activated transcription, as reported previously (Figure 5C; Sheppard
et al., 2001). GRHL2 potently inhibited transcription that was driven
by the complex of p300-IBID and SRC-1 (Figure 5D). Of interest,
mutation of the two lysines (K2086 and K2091) of the IBID domain
that are acetylated in vivo abrogated the ability of the p300-IBID/
SRC1 complex to activate transcription (Figure 5E). These results
indicate that the transcriptional activation by the p300 C-terminus,
which is supported by SRC-1 and abrogated by GRHL2, depends
on acetylation of at least these (and probably other) lysines by p300
HAT or perhaps other GRHL2-sensitive HATs that remain to be
determined.
Molecular Biology of the Cell

FIGURE 3: GRHL2 suppresses AP-1 and p300 function. (A) GRHL2 suppresses AP1 function.
HT1080 and 293T cells were cotransfected with AP-1 response element-luciferase reporter
construct and GRHL2 expression vector or empty vector. PMA was used to induce AP-1
signaling in 293T cells. Values represent relative luciferase activity normalized to TK-βgalactosidase control. (B) Venn diagram comparing GRHL2-repressed genes (Farris et al., 2016)
vs. p300 target genes identified via E1a (Ferrari et al., 2014). (C) GRHL2 suppresses the p300
pathway. p300 effector and target genes induced by HGF in MDCK cells with GRHL2 shRNA vs.
cells with constitutive GRHL2 determined by Ingenuity Pathway Analysis. Quantitation of the
number of unregulated, HGF up-regulated, or HGF down-regulated genes for both cell lines.
The p300 interactome diagram on which this is based is shown in Supplemental Figure S7.
(D) GRHL2 suppresses p300 function. GAL4-minimal promoter-luciferase activation by a
cotransfected GAL4-p300 was assayed in HT1080 cells in the presence or absence of
cotransfected GRHL2 expression vector; values represent relative luciferase activity normalized
to TK-β-galactosidase control.

A small region of GRHL2 inhibits p300 and is critical
for suppressing tubulogenesis and EMT
To identify the region of GRHL2 responsible for p300 inhibition, whole
domains of GRHL2 were deleted initially (Figure 6A) and assayed for
inhibition of HAT activity and transcriptional activation by GAL4-p300.
In light of the lack of GRHL2-binding sites in most GRHL2-repressed
promoters (unpublished data), the surprising result was that the DNAbinding domain (aa 245–494) was critical for inhibition (Supplemental
Figures S15 and S16). Glutathione S-transferase (GST)–GRHL2 protein
subfragments derived from the DNA-binding domain were assayed
for HAT inhibition (Figure 6B). The region of aa 325–475, and within
that, the 13-aa sequence 425–437, inhibited HAT activity potently
(Figure 6C), and a synthetic peptide (aa 420–442) was also able to inhibit p300 HAT activity (Supplemental Figure S15C). The aa 425–437
fragment (IRDEERKQNRKKG) is an α-helix conserved among GRHL1,
Volume 27 August 1, 2016

GRHL2, and GRHL3 (Kokoszynska et al.,
2008). A GRHL2 Δ425-437 construct (with a
synthetic nuclear localization signal) was unable to repress an AP-1-promoter, GAL4P300 transactivation (assayed on a GAL4-Luc
reporter), the MMP1 promoter, or the MMP14
promoter (Figure 6D). We recently reported
that GRHL2 repressed the expression of the
glutamate dehydrogenase-1 gene (GLUD1),
with important consequences for metabolism
and anoikis (Farris et al., 2016). Of interest,
GRHL2 also repressed this promoter in a
manner that required aa 425–437
(Supplemental Figure S17). GRHL2 Δ425-437
was still able to interact, however, with p300
in a cotransfection assay (Supplemental
Figure S18).
We hypothesized that the inhibition of
p300 function could provide a mechanism
for some aspects of transcriptional reprogramming by GRHL2. Consistent with the
inability of the GRHL2 Δ425-437 to repress
the AP1-dependent promoters MMP1 and
MMP14 (Figure 6C), this mutant was unable
to suppress HGF-induced tubulogenesis in
MDCK cells (Figure 7A). Moreover, wildtype GRHL2 reverses EMT in MSP cells, a
cancer stem cell–like subpopulation derived
from the mammary epithelial cell line HMLE
(Cieply et al., 2012, 2013). The GRHL2
Δ425-437 mutant failed to reverse EMT by
the criteria of cell morphology as well as
EMT marker protein and mRNA expression
(Figure 7B). These results indicated that the
inhibition of p300 by GRHL2 contributes
significantly to transcriptional reprogramming involved in both tubulogenesis and
EMT (Figure 8).

DISCUSSION

Previously we proposed that the epithelial
cell is the default phenotype from both developmental and cancer biological points of
view. Under this hypothesis, the epithelial
phenotype is adopted automatically by a cell
in the absence of genomic/epigenetic alterations or inductive differentiation signaling
(Frisch, 1997). Consistent with this idea, E-cadherin–expressing cells
are the first to emerge at the late-two-cell stage; these eventually
give rise to all differentiated cell types of the adult organism (Hyafil
et al., 1980; Vestweber and Kemler, 1985; Fleming et al., 1989; Larue
et al., 1994). The adenovirus-5 E1a protein, which interacts with and
negatively modulates p300, enforces an epithelial phenotype, suppresses EMT, enhances anoikis, suppresses MMP expression, and
exerts a ubiquitously acting tumor suppression effect in human tumor
cells (Frisch and Mymryk, 2002).
The default idea has been invoked in recent studies from other
laboratories to explain, for example, MET occurring at metastatic
sites (Thiery and Sleeman, 2006; Polyak and Weinberg, 2009; Tam
and Weinberg, 2013). The default hypothesis could be explained
molecularly if critical coactivators such as p300 were required for
differentiation-specific but not epithelial-specific gene expression
GRHL2 inhibits EMT through p300
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1999; Sun et al., 2004; Chou et al., 2006;
Clark et al., 2008; Lee and Partridge, 2010;
Santer et al., 2011).
With regard to tubulogenesis, the p300dependent Ets family transcription factors
Etv4 and Etv5 are key transcriptional regulators of this developmental process (Yang
et al., 1998; Jayaraman et al., 1999; Goel
and Janknecht, 2003; Foulds et al., 2004; Lu
et al., 2009; Oh et al., 2012; Wollenick et al.,
2012). In addition, the family of p300-dependent TCF/β-catenin transcription complexes is a central hub for Wnt signaling,
crucial for nephron induction (Li et al., 2007;
Bridgewater et al., 2008; Miller and McCrea,
2010; Ma et al., 2012).
p300 activates transcription through an
array of mechanisms: acetylation of histones, acetylation of transcription factors,
binding of the p300 bromodomain to acetylated histones to promote transcriptional
activity, and recruitment of histone methylFIGURE 4: GRHL2 suppresses the HAT activity of p300. (A) In vitro HAT assays with
transferases (e.g., Set1b complex; Ogryzko
recombinant H3, p300, and GRHL2 proteins. Coomassie stains to assess the quality of
et al., 1996; Gu and Roeder, 1997; Mizzen
recombinant proteins used throughout this study are shown in Supplemental Figure S19.
and Allis, 1998; Ito et al., 2001; Wolf et al.,
(B) GRHL2 inhibits the acetylation of H3 on GRHL2-repressed but not GRHL2-induced
2002; Stiehl et al., 2007; Chen et al., 2010;
promoters in vivo (ChIP assay). Cross-linked chromatin from HT1080+ vector HT-1080+GRHL2
Tang et al., 2013). By inhibiting p300 HAT
cells immunoprecipitated with H3K27-Ac or rabbit IgG; the indicated promoters were assayed
activity, GRHL2 could enforce an inactive
for H3K27Ac by qPCR using the primers in Materials and Methods. *p < 0.05. GRHL2 does not
state on p300 in at least two ways. First,
affect global histone H3K18-Ac or H3K27-Ac (Western blotting of total histones). (C) GRHL2
p300 HAT activity is substantially increased
interacts with p300. Left, cotransfection of indicated expression constructs, followed by
coimmunoprecipitation/Western blotting. Middle, coimmunoprecipitation of retrovirally
by autoacetylation of an autoinhibitory
expressed, S-tagged GRHL2 with endogenous p300. Right, coimmunoprecipitation of
loop on the HAT domain, which GRHL2
endogenous GRHL2 and endogenous P300.
would suppress, stably inhibiting the enzyme (Thompson et al., 2004). Second, the
(Frisch, 1997). Accordingly, we reported previously that GRHL2,
p300 HAT domain potentiates p300 C-terminal domain (aa 1665–
shown here to antagonize the coactivator p300, inhibits and re2414) transactivation (Stiehl et al., 2007), which GRHL2 blocked.
verses the oncogenic EMT, suppressing tumor initiation, drug resisThe minimal domain for p300 C-terminal transactivation is aa
tance, and anoikis resistance (Cieply et al., 2012, 2013).
2000–2180, which include the IBID (Lin et al., 2001; Matsuda
The novel observation that GRHL2 antagonizes p300-depenet al., 2004). The p300 IBID domain cooperates with SRC1, a
dent pathways in the context of tubulogenesis provides a potenp160/steroid receptor coactivator family member, to activate trantially unifying mechanism for both the developmental and oncoscription (Sheppard et al., 2001). By inhibiting the HAT activity of
logic effects of GRHL2. GRHL2 probably regulates tubulogenesis
p300, GRHL2 suppresses coactivation by the p300-IBID complex,
by additional, p300-independent mechanisms. For example,
which is highly dependent on the two known acetylation sites,
cells that fail to down-regulate GRHL2 appropriately may fail to
K2086 and K2091, for activity. Of interest, SRC1-p300 was shown
down-regulate cell adhesion molecules in response to morphoto induce TWIST expression and EMT in breast cancer (Qin et al.,
genic factors (Werth et al., 2010; Senga et al., 2012). For exam2009), and GRHL2 is a potent EMT suppressor.
ple, E-cadherin relocalizes from cell junctions to diffuse memAlthough >400 DNA-binding proteins interact with p300 and
brane pattern in protrusive cell extensions during tubulogenesis;
use it as a coactivator, the inhibitory effect of GRHL2 on p300 is
this relocalization might be envisioned to require GRHL2 downnearly unique, shared by only one other family of proteins, the E1aregulation and subsequent loss of junctional complex compolike inhibitor of differentiation (EID) proteins. EID1 inhibits p300 HAT
nents in these specific cells (Pollack et al., 1998).
activity (MacLellan et al., 2000), and EID3 blocks the SRC-1/CBP inp300 contributes to tubulogenesis and cancer-related EMT in
teraction; the mechanism of EID2 is controversial (Ji et al., 2003;
multiple important ways, providing a mechanism for GRHL2, via inMiyake et al., 2003; Båvner et al., 2005). To our knowledge, the
hibition of p300, to suppress these processes. With regard to caneffects of EID proteins on EMT or tubulogenesis have not been
cer, transcription factors that use p300/CBP and additional coactivainvestigated.
tors that interact with p300/CBP have been implicated in the
GRHL2 regulates intracellular metabolism, and this could indioncogenic EMT, tumor drug resistance, and tumor recurrence
rectly affect p300 by altering the levels of the cofactors for p300
(Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou
HAT, acetyl-CoA, or crotonyl-CoA (Li and Li, 2015; Farris et al.,
et al., 2012; Delvecchio et al., 2013; Ringel and Wolberger, 2013;
2016). This may provide an additional, more indirect mechanism for
Yang et al., 2013; Xu et al., 2014; Cho et al., 2015). The up-regulaGRHL2 to affect p300 function.
tion of MMPs associated with the oncogenic EMT requires AP-1,
In summary, p300 and related coactivators are crucial for cells to
Ets, and other p300-dependent factors (Westermarck and Kähäri,
differentiate. Under the default-phenotype hypothesis, this can be
2484 | P. M. Pifer et al.
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extended to critical roles in EMT in contexts such as tubulogenesis
and oncogenesis. The inhibition of p300 by GRHL2 provides a
mechanism for GRHL2 to enforce the default epithelial
phenotype.

MATERIALS AND METHODS
Cell lines
The 293 HEK cells without T antigen (Doug Black, University of
California, Los Angeles [UCLA], Los Angeles, CA), MDCK cells
(clone M8; Frisch and Francis, 1994), and HT1080 cells (American
Type Culture Collection [ATCC], Manassas, VA) were cultured in advanced DMEM (Life Technologies, Carlsbad, CA) with 10% fetal bovine serum (FBS; Hyclone, Chicago, IL) and 1× penicillin-streptomycin-glutamine (PSG) (Invitrogen, Carlsbad, CA). miMCD-3 cells
(ATCC) were cultured in advanced DMEM:Ham’s F-12 (Life Technologies) with 10% FBS and 1× PSG. The HMLE and HMLE MSP
cells were described previously (Cieply et al., 2013).

Generation of stable cell lines by retroviral transduction
and lentiviral transduction
Full-length GRHL2/pMXS-IRES-Puro and retroviral packaging protocol were described previously (Farris et al., 2016). GRHL2 Δ425437 was subcloned into pMXS-IRES-Puro from GRHL2 Δ425-437NLS-3xFLAG/pCDNA3.1+. GRHL2 shRNA/pGipZ and scramble
control shRNA/pGipz were obtained from Open Biosystems and
packaged as previously described (Cieply et al., 2012). The shRNA
construct in pTRIPZ was made by subcloning an MluI-XbaI fragment
from pGIPZ.

Cell scattering assays
MDCK cells were plated on collagen-coated six-well dishes to give
25% cell confluency on HGF induction. Cells were treated with
60 ng/ml recombinant human HGF (RD Systems, Minneapolis, MN)
in DMEM or fresh DMEM for the time periods indicated. The cells
were imaged and then harvested for protein or RNA analysis. Images were obtained using a Zeiss Axiovert 200M, AxioCam MRM
camera, Phase 20×/0.55 objective, room temperature, and Axio
Vision, release 4.8 software. Cell scattering time-lapse movies were
taken every 15 min over a 24-h period. Time-lapse images were
obtained using a Nikon Eclipse TE2000-E with Photometrics CoolSNAP HQ2 Monochrome charge-coupled device with a Phase
40×/0.75 objective using a Bioptechs Delta T4 Culture Dish Heater,
Prior ProScan II Encoded Motorized Stage, and Oko Labs Digital
Stage Top Incubator (37°C/5% CO2). For each data point, four 40×
images were stitched together using 10% overlap with background
correction in NIS-Elements AR (Nikon).

Western blotting

FIGURE 5: GRHL2 inhibits the C-terminal transactivation domain of
p300. (A) The p300 HAT domain stimulates transactivation by the
p300 C-terminus (cotransfection in HT1080 cells). (B) GRHL2 inhibits
transactivation by the p300 C-terminus. HT1080 cells were
cotransfected with GAL4 response element luciferase reporter in the
presence of the indicated expression constructs. (C) The IBID domain
of p300 and the coactivator SRC-1 synergize to activate transcription.
HT1080 cells were cotransfected with GAL4 response element
luciferase reporter I in the presence of the indicated expression
constructs. (D) GRHL2 inhibits transactivation by the IBID-SRC-1
complex. HT1080 cells were cotransfected with GAL4 response
element luciferase reporter in the presence of the indicated
Volume 27 August 1, 2016

Protein lysates were incubated at 95°C for 5 min in 1× SDS lysis buffer (125 mM Tris-HCl, pH 6.8, 0.04% SDS, 0.024% bromophenol
blue, 5% β-mercaptoethanol, and 20% glycerol). SDS–PAGE was
run in a 4–20% gradient Novex Tris-glycine gel (Invitrogen). Proteins
were electrophoretically transferred to a polyvinylidene difluoride

expression constructs. (E) Transactivation by the IBID-SRC-1 complex
is contingent upon lysines 2086 and 2091. HT1080 cells were
cotransfected with GAL4 response element luciferase reporter in the
presence of the indicated expression constructs. In A–E, values
represent relative luciferase activity normalized to TK-β-galactosidase
control. (F) Schematic of p300 domains. Bd, bromodomain; HAT,
histone acetyltransferase domain; IBID, IRF-3 binding domain; KIX,
CREB-binding domain.
GRHL2 inhibits EMT through p300
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MDCK tubulogenesis assay
MDCK tubulogenesis assay was performed
as previously described (Elia and LippincottSchwartz, 2009). Briefly, collagen matrix was
made by mixing 10× MEM (Invitrogen), 100×
PSG, 23.5 g/l NaHCO3 (Invitrogen), sterile
water, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Invitrogen) to working concentrations. Vitrogen bovine collagen (5005-b; Advanced Biomatrix, Carlsbad,
CA) was added to a final concentration of 2
mg/ml. NaHCO3 was used to bring the solution to pH 7.3 via a pH strip indicator (Elia
and Lippincott-Schwartz, 2009). In a 24-well
plate, 100 μl of working collagen solution
was placed in a 1.0-μm-pore cell culture insert (Falcon, Franklin Lakes, NJ) and allowed
to solidify for 3 h in tissue culture incubator.
Subconfluent MDCK cells were trypsinized
and counted using a Countess Cell counting
machine (Invitrogen). Cells were pipetted
into the working collagen solution to give a
final concentration of 5000 cells/ml. Then
250 μl of cell/collagen solution was pipetted
onto the presolidified collagen matrix in the
cell culture insert. The cell–collagen matrix
was allowed to solidify for 2 h at 37°C and
5% CO2, and then 250 and 500 μl of medium was placed on the cell–collagen matrix
cell culture insert and in a 24-well chamber,
respectively. Media were changed every 3 d.
After 6 d, 60 ng/ml recombinant human
FIGURE 6: A small region within the DNA-binding domain of GRHL2, aa 425–437, inhibits p300.
HGF was added to indicated wells, and
(A) Schematic of GRHL2 domains. DBD, DNA-binding domain; DD, dimerization domain; TAD,
branching morphogenesis was monitored
transactivation domain. (B) HAT assays using the indicated GRHL2 fragments, assayed as
by microscopy. MDCK cyst staining was perGST-fusion proteins. (C) GRHL2 aa 425–437 inhibits p300 HAT activity. The indicated fragments
formed as previously described (Elia and
derived from GRHL2 were assayed as GST-fusions (left) or recombinant peptides (right) for
Lippincott-Schwartz, 2009), with the only
inhibition of HAT activity. (D) GRHL2 aa 425–437 are required for inhibition of an AP-1 reporter,
modification being the substitution of 7 mg/
GAL4 reporter in conjunction with GAL4-p300, MMP1 reporter, or MMP14 reporter. Values
represent relative luciferase activity normalized to TK-β-galactosidase control.
ml fish-skin gelatin for Triton X-100 in permeabilization buffer. Cysts were stained with
membrane (Immobilon, Waltham, MA) in Tris-glycine buffer with 5%
Alexa Fluor 488–phalloidin (Molecular Probes, Eugene, OR) and
methanol. Membranes were blocked for 1 h in 1× Tris-buffered
Hoescht 33258 (Molecular Probes). Representative 2-d post-HGF
saline (TBS) plus 5% nonfat milk. Primary and secondary antibodies
images were obtained using a Zeiss 710 Confocal with Airyscan,
were incubated in 1× TBS plus 5% nonfat milk plus 0.1% Tween-20.
Apochromat 40×/1.2 W Autocorr M27, room temperature, Axio
Primary antibodies were incubated for 2 h at room temperature or
Observer.Z1 software, and diode 405-nm and argon 488-nm lasers.
overnight at 4°C at 1:1000 dilution. Primary antibodies used were
Images were processed in Photoshop (Adobe). Tubulogenesis was
as follows: GRHL2, rabbit (rb; Sigma-Aldrich, St. Louis, MO); β-actin,
observed by day 2 after HGF addition and quantified on day 5 after
mouse (ms; Thermo Pierce); fibronectin, ms (BD Biosciences, FrankHGF addition.
lin Lakes, NJ); vimentin, ms (Santa Cruz Biotechnology, Dallas, TX);
β-actin, ms (Sigma-Aldrich); E-cadherin, ms (BD Biosciences); βRNA-Seq Assay
catenin, ms (BD Biosciences); glyceraldehyde-3-phosphate dehyMDCK+GRHL2/pMXS and MDCK+shGRHL2/Gipz cells were plated
drogenase (GAPDH), ms (OriGene, Rockville, MD); acetyl-lysine, rb
in collagen-coated, 60-mm2 dishes to obtained 25% confluency
(Millipore); H3K18AC, rb (Cell Signaling, Danvers, MA); H3K27AC,
upon HGF treatment. Cells were treated with either 60 ng/ml HGF
rb (Cell Signaling); total H3, rb (Cell Signaling); GST, ms (Thermo
in DMEM complete or DMEM complete alone for 24 h; RNA was
Pierce, Waltham, MA); p300, rb (sc-584; Santa Cruz Biotechnology);
isolated from all four treatment conditions in triplicate using the
p300, rb (sc-585; Santa Cruz Biotechnology); FLAG, ms (Sigma-AlRNeasy Plus Kit (Qiagen) and quantified using NanoDrop (Fisher,
drich); and GAL4, rb (Santa Cruz Biotechnology). Goat anti-rabbit or
Waltham, MA). Raw data were aligned to the CanFam3 reference
anti-mouse horseradish peroxidase–conjugated secondary antigenome using TopHat2 (Kim et al., 2013). For each sample and each
bodies (Bio-Rad) were used at 1:3000 dilution and incubated for 1
gene, the number of reads generated from that sample and
h at room temperature RT. Western blot membranes were develmapping to that gene were counted using RSamtools. Genes were
oped using ECL-West Pico (Pierce) and analyzed using standard
as defined in the ensembl database, version 82 (Cunningham et al.,
chemiluminescence techniques.
2015). The resulting count table was analyzed using DESeq
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FIGURE 7: The p300-inhibitory domain of GRHL2 is important for the suppression of tubulogenesis and reversion of
EMT. (A) MDCK cells expressing GRHL2 wild-type or GRHL2 Δ425-437 were assayed for tubulogenesis (blue, nuclei;
green, actin). Scale bar, 20 μm. Middle, quantitation; right, Western blot confirmation of protein levels. (B) MSP cells
expressing GRHL2 wild-type or GRHL2 Δ425-437 were assayed for reversion of EMT by Western blotting for EMT
markers (left), cell morphology (middle), or qPCR (right).

(Anders and Huber, 2010) with two independent comparisons: samples with HGF compared with those without or with GRHL2 overexpressed, and samples with HGF compared with those without, both
expressing GRHL2 shRNA. Genes were considered differentially
expressed if they showed a false discovery rate of ≤0.05 and a fold
change of ≥1.5 in either direction. Genes regulated by HGF with
shRNA against GRHL2 but not regulated by HGF with GRHL2 overexpressed were uploaded to Ingenuity Pathway Analysis (Qiagen),
where a Core Analysis was performed using default settings.

Quantitative reverse transcription PCR analysis
MDCK parent, GRHL2/pMXS, and shGRHL2/pGipZ cells were plated
on collagen-coated 60-mm2 dishes and treated as indicated. Cells
were harvested using RNEasy Plus minikit (Qiagen, Hilden, Germany),
analyzed using NanoDrop, and converted to cDNA using SuperScript
Volume 27 August 1, 2016

FIGURE 8: GRHL2 suppresses tubulogenesis and EMT by inhibition
of p300.
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III First-Strand Synthesis SuperMix (Invitrogen) with oligo dT primers
and 1 μg of RNA. cDNA was analyzed using SYBR Green PCR Master
Mix on an Applied Biosystems 7500 Real Time PCR System. Values
reported were determined using the ΔΔCT method using canine
CBX1 as internal control. Primers were as follows: CBX1-F (AAGTATTGCAAGGCCACCCA), CBX-R (TTTTCCCAATCAGGCCCCAA),
GRHL2-F
(TTCCTCCCCAGGAGAGATGG),
GRHL2-R
(GG
CCCAACACACGGATAAGA), MMP1-F (TGACTGGAAAGGTCGACACG), MMP1-R (GACCTTGGTGAAGGTCAGGG), MMP3-F (CTG
ACCC
TAGCGCTCTGATG), MMP3-R (GTCCTGAGGGATTTTCGCCA), MMP13-F (GGACTTCCCAGGGATTGGTG), MMP13-R (ATGACACGGACAATCCGCTT), MMP14-F (CCCAGAGGAGGGCATGTTTT), MMP14-R (GACTCCCCACCCTTCCAATG), FOS-F (GGGA
GGACC
TTATCTGTGCG), FOS-R (ACACACTCCATGCGTTTTGC),
FOSL1-F (ACACCCTCCCTGACTCCTTT), FOSL1-R (CTGAAGA
GGGCAT
GGGATTA), FOSB-F (GGAGAAGAGAAGGGTTCGCC),
FOSB-R (CACAAACTCCAGACGCTCCT), JUN-F (GACCTTCTACGACGATGCCC), JUN-R (TTCTTGGGGCACAGGAACTG), JUNB-F
(GTGAAGACACTCAAGGCCGA), and JUNB-R (AGACTGGGGG
AATGTCCGTA).

Luciferase reporter assays
HT1080 or 293 NOT cells were transiently transfected using Lipofectamine 2000 (Invitrogen) at 1 μg of DNA:3 μl of Lipofectamine.
After 20 min of incubation in 300 μl of Opti-MEM (Invitrogen), 1.0 μg
DNA was transfected into a 12-well plate with DMEM and refed 4 h
later with DMEM. After 28–36 h posttransfection, the cells were
washed twice with cold phosphate-buffered saline (PBS), lysed in
200 μl of 1× Cell Culture Lysis Buffer (Promega), frozen for at least
1 h at −80°C, thawed on ice, and centrifuged at 13,200 rpm. The
supernatants were assayed for luciferase activity (Promega, Madison, WI) and β-galactosidase activity as internal control (2×
β-galactosidase assay reagent, 200 mmol/l sodium phosphate,
pH 7.3, 2 mmol/l MgCl2, 100 mmol/l 2-mercaptoethanol, and
1.33 mg/ml o-nitrophenylgalactoside). MMP1 promoter (−1200 to
+60) and MMP14 promoter (−1114 to −242) luciferase reporter
plasmids were generated by subcloning the promoter from genomic DNA using PCR into the pGL3-basic luciferase reporter
plasmid. Primer sequences were MMP1prom-F (TTATTACTCG
AGCCCT
CCCTCTGATGCCTCTGA), MMP1prom-R (TATATAAA
GCTTCTCCAATATCCCAGCTAGGAA), MMP14prom-f (TTATTAC
TCGAGCCCTTTCTCACGGTCAGCTT), and MMP14prom-R (TAT
ATAAAGCTTTCTCGCTCTCTCCTCTGGTC). GRHL2/pcDNA3.1,
TK-LacZ, and E1a/pCDNA3.1 plasmids were described previously
(Grooteclaes and Frisch, 2000; Cieply et al., 2012). E1A p300
binding mutant was a generous gift from Arnold Berk (UCLA) subcloned into pCDNA3.1+. GRHL2 Δ425-437 was generated by
cloning GRHL2 aa 1–424and 438–625 fragments and ligating together with Bglll and then ligating into pCDNA3.1+ using BamHI
and Sal1. Primers used were GRHL2-1-424-F (TATATAGGATCCATGTCACAAGAGTCGGACAA), GRHL2-1-424-R (ATATAAAGATCTT
TTTCTTTCTGCTCCTTTGT), GRHL2-438-625-F (TAAATTAGATCT
AAAGGCCAGGCCTCCCAAAC), and GRHL2-438-625-R (TTATATGTCGACCTAGATTTCCATGAGCGTGA). pGL4.44[luc2P/AP1 RE/
Hygro] (Promega) was used to assay for AP-1–responsive promoter
activity, and control plasmid was pGL4.27 (Promega). Phorbol
12-myristate 13-acetate (PMA) induction (10 ng/ml; Thermo Fisher)
was used for assaying AP-1 activity in transfected 293 cells. Fulllength p300-GAL4/VR1012 and EV-GAL4/VR1012 were generous
gifts from Neil Perkins (Newcastle University, Newcastle upon
Tyne, United Kingdom); they were assayed on the GAL4 responsive reporter pG5-Luc (Promega). GAL4- p300 HAT (aa 1283–
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1674), GAL4- p300C-terminus (aa 1665–2414), and GAL4- p300
IBID (aa 2050–2096) were generated by subcloning PCR fragments
(MluI-NotI) into pBIND (Promega). Primer sequences were p300
C-terminal-F (TATATAACGCGTATCGCTTTGTCTACACCTGCAAT),
p300 C-terminal-R (TTTAAAGCGGCCGCCTAGTGTATGTCTAGTGTAC), p300 HAT-F (TATATAACGCGTATAGGAAAGAAAATAAG
TTTTCT), p300 HAT-R (TTTAAAGCGGCCGCCTAGTCCTGGCTCTGCGTGTGCAG), p300 IBID-F (TATATAACGCGTATGCCTTACAAAACCTTTTGCG), and p300 IBID-R (TTTAAAGCGGCC
GCCTAATTAGAGTTGGCATACTTGG). To generate the p300-IBID
mutant (K2086A and K2091A), the p300 IBID lysine nucleotide
sequences were mutated to alanine, and flanking Mlu1 and Not1
restriction enzymes were added to the 5′ and 3′ ends, respectively.
The sequence was then generated as a gBlock gene fragment
(IDT). The p300 mutant sequence was 5′ CACAACCAGG
ATTGGGCCAG GTAGGTATCA GCCCACTCGC ACCAGGCACT
GTGTCTCAAC AAGCCTTACA AAACCTTTTG CGGACTCTCA
GGTCTCCCAG CTCTCCCCTG CAGCAGCAAC AGGTGCTTAG
TATCCTTCAC GCCAACCCCC AGCTGTTGGC TGCATTCATC GCGCAGCGGG CTGCCGCGTA TGCCAACTCT AATCCACAAC 3′.
The IBID mutant fragment was digested and ligated into pBIND
vector. HA-SRC1/pACTAG was a generous gift from Timothy Beischlag (Simon Fraser University, Burnaby, Canada).

Immunoprecipitation
GRHL2-STAP contained full-length human GRHL2 fused to a C-terminal myc–streptavidin binding peptide (SBP)–S-tag sequence derived by ligating a synthetic oligonucleotide containing the S-tag to
a PCR product containing the myc-SBP tags from the pCeMM-CTAP
vector (Burckstummer et al., 2006). The 293 NOT cells were plated
on collagen-coated six-well dishes and transfected using 1 μg of
empty vector/pCDNA3.1+ or GRHL2-S-TAP/pCDNA3.1+ and 1 μg
of empty vector/VR1012 or p300/VR1012) with 6 μl of Lipofectamine
(Invitrogen) in 300 μl of Opti-MEM (Invitrogen). Cells were incubated
for 4–6 h with DMEM and then refed with DMEM. At 28 h posttransfection, cells were lysed in 600 μl of cold p300 lysis buffer (25 mM
Tris-HCl, pH 8, 75 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.1% NP40, and protease inhibitor tablet [Roche, Basel, Switzerland]). Sample
lysates were passed through a 1-ml syringe with a 27-gauge needle
three times and precleared in a 4°C microcentrifuge at 13,200 rpm
for 10 min. Total lysate samples were obtained, mixed 1:1 with 2×
SDS lysis buffer (250 mM Tris-HCl, pH 6.8, 0.08% SDS, 0.048% bromophenol blue, 10% β-mercaptoethanol, 40% glycerol) and heated
for 5 min at 95°C. Lysates were precipitated for 2 h with 40 μl of 50%
S protein-agarose (EMD Millipore, Billerica, MA) that had been preequilibrated with p300 lysis buffer containing 10 mg/ml bovine serum albumin (BSA). Immunoprecipitation lysates were washed three
times with p300 lysis buffer, diluted with 2× SDS lysis buffer, and
heated for 5 min at 95°C. Lysates were processed using previously
described Western blotting methods. For endogenous p300 and ectopic GRHL2 coimmunoprecipitation, MSP cells with empty vector/
pMXS or GRHL2/pMXS were used in the experiment. For endogenous p300 and endogenous GRHL2 coimmunoprecipitation, parental HMLE cells were used in the experiment. The coimmunoprecipitation method was identical between the different cell lines. For each
cell line, two 100-mm dishes were grown to 80% confluency, washed
twice with cold PBS, lysed in 1 ml of p300 lysis buffer with protease
inhibitors, and passed three times through a 27-gauge needle. After
lysates were precleared at 13,200 rpm, 10 μg of p300 antibody
(SCBT, SC-584) or rabbit immunoglobulin G (IgG; Jackson, Bar
Harbor, ME) was added to lysates and incubated overnight on a 4°C
wheel. Preequilibrated Protein A-Sepharose (45 μl; GE Healthcare)
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was added and incubated for 90 min. Samples were washed three
times in p300 lysis buffer, 45 μl of 2× SDS lysis buffer was added, and
samples were heated at 95°C for 5 min. Lysates were processed using previously described Western blotting methods.

Histone acetylation assays
Histone acetylation reactions contained indicated amounts of recombinant baculovirus Flag-tagged p300 (37.5 ng; Active Motif,
Carlsbad, CA) or baculovirus p300 HAT (1283-1673; Sigma-Aldrich),
250 ng of H3 (Cayman), 100 μM acetyl-CoA (MP Biomedical, Santa
Ana, CA), and indicated amounts of PreScission-cleaved GRHL2,
GST-GRHL2, or GST alone in 30 μl of p300 acetylation buffer
(50 mM Tris-HCl, pH 8.0, 1 mM dithiothreitol [DTT], 0.1 mM EDTA,
10% glycerol, and protease inhibitor). Acetylation reactions were
incubated for 15 min at 30°C on heat block. Reactions were diluted
with 2× SDS lysis buffer and incubated for 5 min at 95°C. Lysates
were processed using previously described Western blotting
methods.

Recombinant protein purification
Full-length GRHL2 was subcloned into pGEX-6P-3 vector (GE
Healthcare) and transformed into BL21 bacteria (Invitrogen).
GRHL2 fragments were subcloned into pGEX-6p-3 using BamH1
and Sal1. A colony was selected and grown in 20 ml of LB+amp
overnight at 37°C. The next day, 10 ml of culture was inoculated
into 500 ml of LB+amp and incubated for ∼2 h at 37°C with shaking until OD ≈ 0.6 was obtained. Isopropyl-β-d-thiogalactoside
was added to final concentration of 0.1 mM and incubated overnight on a shaker at room temperature. The bacteria were spun in
a chilled centrifuge for 10 min at 5000 rpm. Bacterial pellet was
resuspended in 10 ml of BL21 lysis buffer (1× PBS, 1% Triton-100,
1 mM DTT, 0.4% lysozyme, and protease inhibitor tablet), incubated for 10 min, and sonicated twice for 30 s. The suspension was
cleared at 13,000 rpm for 10 min. A 150-μl amount of 50% glutathione-Sepharose beads (GE Healthcare, Little Chalfont, United
Kingdom) was added to the supernatant, which was incubated for
2 h with rotation at 4°C. Glutathione-Sepharose beads were
washed three times with glutathione washing buffer (1× PBS, 1 mM
DTT, and 0.1% Triton-X) and eluted for 30 min with glutathione
elution buffer (100 mM Tris, pH 8, 150 mM NaCl, 20 mM glutathione, and protease inhibitors). Alternatively, glutathione-Sepharose
beads with GRHL2 protein attached were washed three times in
PreScission cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT, pH 7.0). The GST-GRHL2 on glutathione-Sepharose beads was cleaved by adding 80 μl of PreScission Protease
(GE Healthcare) per milliliter of PreScission cleavage buffer at 5°C
overnight. The sample was spun at 2000 rpm, and the supernatant
with the GST-cleaved GRHL2 was obtained. Proteins were dialyzed
against p300 acetylation buffer overnight at 4°C using a 20,000
MWCO Slide-A-Lyzer MINI Dialysis Unit (Thermo Scientific). Protein was analyzed on SDS–PAGE by Coomassie blue staining and
quantified by comparison of Coomassie staining to a BSA standard and/or a bicinchoninic acid assay. Synthetic peptides were
purchased from ThermoFisher Scientific with N-terminus acetyl
group and C-terminus amidation: GRHL2 aa 420–442 (GAERKIRDEERKQNRKKGKGQAS) and scramble (IDEKNKGRERQRK)

Chromatin immunoprecipitation
For ChIP assay, HT1080 cell lines expressing empty vector/pMXS or
GRHL2/pMXS cells were used and chromatin generated as described
previously, with the following modifications (Kumar et al., 2011):
1) Immunoprecipitation was performed with 3 μg of H3K27-Ac antiVolume 27 August 1, 2016

body (Cell Signaling) or rabbit IgG (Jackson) to 3.3 × 106 cell equivalents in ChIP RIPA buffer. 2) Protein A-Sepharose was used instead of
FLAG-agarose beads. 3) qPCR was performed using 2× SYBR Green
Master Mix (10 μl; Applied Biosystems, Foster City, CA), 0.08 μl of
100 mM primer, and 1 μl of ChIP DNA in a 20-μl reaction. Primer
sequences were as follows: MMP1-1-F (AACCTCAGAGAACCCCGAAG), MMP1-1-R (TACTAACACTGCGCACCTGA), MMP1-2-F
(CAGAGTGGGGCATGAGTAGG), MMP1-2-R (TGTCTTCGGTACTGGTGACC), MMP14-F (AAGTAAGTGAGCTTCCCGGC), MMP14-R
(GGAGTTCGCCCCA
GTTGTAA), MMP2-F (TCGCCCATCATCAAG
TTCCC), MMP2-R (CCCCCAAGCTGTTTACCGAA), ZEB1-1-F (GCG
AGGCGTGGGACTGATGG), ZEB1-1-R (AAAGTTGGAGGCTCGGCGGC), ZEB1-2-F (CTGCACGGCGATGACCGCT), ZEB1-2-R (TTCCGCTTGCCAGCAGCCTC), CDH1-F (ACTCCAGGCTAGAGGGTCACC), CHD1-R (CCGCAAGCTCACAGCTTTGCAGTTCC), ESRP1F (GGGAGC
TTGGTCAAGTCAAC), ESRP1-R (TCTTAAATCGGGCCACGCAG), RAB25-F (AGGTCCTGTCCCTTTTTCGC), RAB25-R
(TTGGGGGTAAGGGGACTTCT), GAPDH-F (ATGGTTGCCACT
GGGGATCT), and GAPDH-R (TGCCAAAGCCTAGGGGAAGA).
Results were normalized to GAPDH values.

Ex vivo kidney culture
All experiments involving mice were approved by the West
Virginia University Institutional Animal Care and Use Committee.
Hoxb7creEGFP transgenic mice and the ex vivo kidney culture
method were described previously (Zhao et al., 2004). We removed embryonic kidney at embryonic day 13.5 and cultured
the kidneys in 1 μM batimastat (Tocris, Bristol, United Kingdom)
or vector in culture medium for 48 h. Images were taken of GFP
ureteric buds on an Olympus MVX10 Macro Zoom, ORCA-Flash
4.0 Monochrome camera, objective 2×, zoom 4×, fluorescein isothiocyanate, and using CellSen Imaging Software. Ureteric buds
were counted for quantification.

Confocal microscopy of transfected RRE.1 cells
RRE.1 cells, wild-type e1a-NLS-LacI-mCherry, and empty vector
NLS-LacI-mCherry were generous gifts from Arnold Berk, and the
experiment was performed as previously described (Verschure
et al., 2005; Ferrari et al., 2014). GRHL2 was subcloned into empty
vector NLS-LacI-mCherry using Sal1. Images were taken on a Zeiss
Axioimager Z1 microscope, LSM 510 confocal, 63×/0.75 LDPlanneofluar, 4′,6-diamidino-2-phenylindole and rhodamine, and Zeiss
Zen software. Images were quantified using mean area on ImageJ
(National Institutes of Health, Bethesda, MD).

Statistical analysis
Error bars in graphs represent SD. p values were calculated using a
Student’s two-tailed t test.
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